MEMO1, or Mediator of ErbB2-driven cell motility 1, is a protein that has been identified as a crucial component in the signaling pathways that regulate cell motility, migration, and other aspects of cellular behavior, including cell proliferation and survival. The functional implications of MEMO1 are particularly significant in the context of its interaction with receptor tyrosine kinases, such as ErbB2, where it plays a role in transducing signals that contribute to the dynamic reorganization of the cytoskeleton and cellular adhesion complexes. This involvement is essential for the processes that underlie cell movement, a fundamental aspect of various physiological and pathological processes, including wound healing, immune responses, and the metastatic spread of cancer cells. By facilitating the intricate signaling cascades that govern these cellular activities, MEMO1 emerges as a critical mediator of cellular responsiveness to external stimuli, modulating the cellular architecture and behavior in response to environmental cues.
The inhibition of MEMO1's activity represents a complex regulatory mechanism that can impact cellular motility and other related processes. This inhibition can occur through various mechanisms, including the modulation of MEMO1 expression levels, the disruption of its interactions with key signaling proteins, or through post-translational modifications that affect its functionality. For instance, the suppression of MEMO1 expression through genetic silencing or the use of small interfering RNAs (siRNAs) can lead to diminished cell motility, illustrating the importance of MEMO1 in the signaling pathways that facilitate cellular movement. Additionally, the post-translational modification of MEMO1, such as phosphorylation or ubiquitination, may alter its ability to interact with partner proteins or affect its stability and localization within the cell, thereby modulating its activity in signaling pathways. These mechanisms of inhibition are critical for the fine-tuning of cellular responses to external signals, ensuring that cell motility and other behaviors are appropriately regulated in accordance with the physiological context and environmental conditions. Understanding the intricacies of MEMO1 inhibition offers valuable insights into the cellular mechanisms that govern motility and migration, with implications for the development of strategies to modulate these processes in disease contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. Given that PKC-mediated phosphorylation can enhance MEMO1 activity, inhibiting PKC with staurosporine can indirectly lead to the diminished activity of MEMO1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Given that PI3K/AKT pathway can activate MEMO1, inhibiting PI3K with LY294002 can lead to decreased MEMO1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. By inhibiting PI3K, it can decrease the activation of the PI3K/AKT pathway, leading to reduced MEMO1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a non-ATP competitive inhibitor of MEK. By inhibiting MEK, it can reduce the activation of ERK downstream, leading to reduced MEMO1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Since JNK can phosphorylate and activate MEMO1, inhibiting JNK with SP600125 can lead to decreased MEMO1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, which can phosphorylate and activate MEMO1. Therefore, inhibiting p38 MAPK with SB203580 can lead to decreased MEMO1 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK1 and ROCK2. Given that ROCKs are downstream effectors of MEMO1 in the RhoA pathway, inhibiting ROCKs with Y-27632 can decrease the feedback activation of MEMO1. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB activation. As NF-κB can enhance the expression of MEMO1, inhibiting NF-κB can lead to decreased MEMO1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Given that mTOR signaling can induce MEMO1 activation, inhibiting mTOR with rapamycin can lead to decreased MEMO1 activity. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is a potent and selective inhibitor of RAF1. Given that RAF1 is upstream of ERK, which can activate MEMO1, inhibiting RAF1 with ZM 336372 can lead to reduced MEMO1 activity. | ||||||